The FDA wishes to inform physicians of the removal from the market of troglitazone (Rezulin, Parke-Davis/Warner-Lambert Co, Morris Plains, NJ), a treatment for type 2 diabetes mellitus, and cisapride (Propulsid, Janssen Pharmaceutica Inc, Titusville, NJ), a treatment for severe heartburn.
Troglitazone has been associated with rare but severe liver toxicity since 1997, and close monitoring of liver function of patients using the drug was recommended. A year ago, when it was the only drug of an important class, an FDA advisory committee recommended that troglitazone continue to be available for patients whose disease was not well-controlled by other medications, on the grounds that its benefit to the great majority of patients far outweighed the risk.
Henney JE. Withdrawal of Troglitazone and Cisapride. JAMA. 2000;283(17):2228. doi:10.1001/jama.283.17.2228